[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 73, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 56, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 925331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 57, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 820594, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 45, "title": "CFO & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 573362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.59, "open": 1.63, "dayLow": 1.58, "dayHigh": 1.64, "regularMarketPreviousClose": 1.59, "regularMarketOpen": 1.63, "regularMarketDayLow": 1.58, "regularMarketDayHigh": 1.64, "payoutRatio": 0.0, "beta": 0.9, "forwardPE": -3.809524, "volume": 941848, "regularMarketVolume": 941848, "averageVolume": 2613223, "averageVolume10days": 1657810, "averageDailyVolume10Day": 1657810, "bid": 1.56, "ask": 1.66, "bidSize": 16, "askSize": 16, "marketCap": 328003200, "fiftyTwoWeekLow": 1.19, "fiftyTwoWeekHigh": 4.32, "priceToSalesTrailing12Months": 39.361958, "fiftyDayAverage": 1.7, "twoHundredDayAverage": 2.218375, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 252525616, "profitMargins": 0.0, "floatShares": 128554473, "sharesOutstanding": 205002000, "sharesShort": 25087077, "sharesShortPriorMonth": 23947488, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.1224, "heldPercentInsiders": 0.18337, "heldPercentInstitutions": 0.83191, "shortRatio": 11.43, "shortPercentOfFloat": 0.16149999, "impliedSharesOutstanding": 205002000, "bookValue": 0.349, "priceToBook": 4.584527, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -89298000, "trailingEps": -0.36, "forwardEps": -0.42, "enterpriseToRevenue": 30.304, "enterpriseToEbitda": -2.958, "52WeekChange": -0.47000003, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 1.6, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.59091, "targetMedianPrice": 7.0, "recommendationMean": 1.36364, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 139036000, "totalCashPerShare": 0.678, "ebitda": -85376000, "totalDebt": 63559000, "quickRatio": 5.301, "currentRatio": 5.419, "totalRevenue": 8333000, "debtToEquity": 88.863, "revenuePerShare": 0.033, "returnOnAssets": -0.32506, "returnOnEquity": -1.2194, "grossProfits": 8333000, "freeCashflow": -48153876, "operatingCashflow": -81225000, "revenueGrowth": -0.439, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -9.857571, "financialCurrency": "USD", "symbol": "TSHA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "corporateActions": [], "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1600954200000, "postMarketChangePercent": 0.624999, "postMarketPrice": 1.61, "postMarketChange": 0.00999999, "regularMarketChange": 0.00999999, "regularMarketDayRange": "1.58 - 1.64", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2613223, "fiftyTwoWeekLowChange": 0.40999997, "fiftyTwoWeekLowChangePercent": 0.34453776, "fiftyTwoWeekRange": "1.19 - 4.32", "fiftyTwoWeekHighChange": -2.7200003, "fiftyTwoWeekHighChangePercent": -0.6296297, "fiftyTwoWeekChangePercent": -47.000004, "earningsTimestamp": 1740574800, "earningsTimestampStart": 1747080000, "earningsTimestampEnd": 1747425600, "earningsCallTimestampStart": 1740576600, "earningsCallTimestampEnd": 1740576600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.36, "epsForward": -0.42, "epsCurrentYear": -0.38, "priceEpsCurrentYear": -4.2105265, "fiftyDayAverageChange": -0.100000024, "fiftyDayAverageChangePercent": -0.05882354, "twoHundredDayAverageChange": -0.61837494, "twoHundredDayAverageChangePercent": -0.2787513, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-09-24", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "postMarketTime": 1740787805, "regularMarketTime": 1740776401, "exchange": "NMS", "messageBoardId": "finmb_665948579", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.6289302, "regularMarketPrice": 1.6, "displayName": "Taysha Gene Therapies", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]